Enteromedics Inc.

hier könnt ein schnell Gap close kommen  

EnteroMedics

EnteroMedics (ETRM) is a development stage medical device company engaged in design and development of devices that use neuroblocking technology to treat obesity, its associated co-morbidities, and other gastrointestinal disorders. This stock closed up 8.5% to $1.27 in Tuesday's trading session.

Tuesday's Range: $1.20-$1.36
52-Week Range: $0.81-$3.70
Tuesday's Volume: 3.68 million
Three-Month Average Volume: 724,771

>>4 Hot Stocks to Trade (or Not)

From a technical perspective, ETRM spiked sharply higher here right above its 50-day moving average of $1.13 with huge volume. This stock briefly flirted with a breakout above its 200-day at $1.31 and above some more near-term overhead resistance at $1.32. Shares of ETRM closed just below those levels at $1.27 with volume that was well above its three-month average action of 724,771 shares.

Traders should now look for long-biased trades in ETRM as long as it's trending above Tuesday's low of $1.20 or above its 50-day at $1.13 and then once it sustains a move or close above Tuesday's high of $1.36 and above more key resistance levels at $1.37 to $1.47 with volume that hits near or above 724,771 shares. If we get that move soon, then ETRM will set up to re-fill some of its previous gap down zone from February that started at $3.  

us  

die 1,45$ knallt es richtig.  

vorbörse 1,61$  

EnteroMedics Inc. (ETRM) may be a largely unknown microcap stock to most investors. The company is in the development stages of making medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. A new research report has shares rising handily.

Canaccord Genuity reiterated its Buy rating, but where the big boost is coming from is that the firm doubled its price target to $3.00 from $1.50 on Tuesday. The prior price target already implied upside of about 28% from the $1.17 close on Monday. This new $3 price target implies upside of a whopping 150% if the call turns out to be correct.

Investors do need to understand that there is risk here. Shares were recently lower on a concern over the FDA decision in the first half of 2014 after it formally responded to the company's premarket approval application. At $1.17, the 52-week range is $0.81 to $3.70, and we would caution that the market cap is a mere $65 million.

Canaccord Genuity's William Plovanic and Kyle Rose made the research call here after traveling with EnteroMedecs' management team. The analysts were quoted in the report as saying:

EnteroMedics expects to respond to those questions within the next 30 days, and an FDA panel meeting is now expected late in the fourth quarter of 2013, or more likely the first quarter of 2014. Given the relative safety of the device, moderate weight loss, and lack of alternatives for obese patients, we believe the likelihood of a positive panel result is high. As such, we are raising our price target and believe the risk/reward is favorable for investors with a speculative risk profile.

The analysts are basing this value on a post-approval valuation of the Maestro System for obesity. The firm is putting a system price at $10,000 to $12,500, and the assumption of $10,000 per implant.

We have seen a gain of more than 8% to $1.27 in the early trading on Tuesday. Less  

would like to add a few under $1.50  

EnteroMedics initiated with a Buy at Lake Street
theflyonthewall.comtheflyonthewall.com – 8 minutes ago
 

kriegen die eine zulassung ! Deshalb unbedingt ein Tag vor der entscheidung abstossen !!

MFG
Chali  

steht schon vor der zulassung über 2$ . alles ander ist mir egal dann bin ich raus. das gap bei 2,50$ zieht gewalltig  

Hallo zusammen, ich bin relativ neu unterwegs...warum denkt ihr, dass es keine Zulassung geben wird?  

15.112013 fällt die Entscheidung  

'auf den 15.11?  

 

 

muss ich mir mal genauer anschauen!!  

Jetzt zündet der 1. Teil, man braucht hier absolut Geduld. Die Aktie wurde vor kurzem von Börsenbriefe empfohlen. Das Ziel soll sogar bei 9 Dollar liegen. Wenn alles glatt läuft, kann
Dies so erfolgreich werden, wie bei der Erfindung des Herzschrittmachers.  
 

sie wird ihren weg machen  

rückt sie ins licht  

60M Outstanding 39 M Float 37.90% held by Institutions 25.73% held By Insiders .Traded 29 mil today!!
Avg Vol (3 month)3: 1,553,190
Avg Vol (10 day)3: 5,235,120
Shares Outstanding5: 60.70M
Float: 39.66M
% Held by Insiders1: 25.73%
% Held by Institutions1: 37.90%
Shares Short (as of Oct 31, 2013)3: 2.78M
Short Ratio (as of Oct 31, 2013)3: 1.80
Short % of Float (as of Oct 31, 2013)3: 7.80%
Shares Short (prior month)3: 2.56M  

 

Was glaubst du, wird sie heute weiter steigen? Oder werden werden erst mal gewinne mitgenommen.  

zukauf 1, 78  

 

Der Artikel, den Du als links reingestellt hast, nach Deinem Zukauf mit 1,78, spricht aber nicht gerade für, sondern gegen Enteromedics.

Oder hab ich da was falsch verstanden?

Bin auch mit einer Mini-Posi drin, aber wie gesagt, der Artikel spricht bei siginifikanter Gewichtsabnahme von selektierter bias die die Signifikanz ausdrückt.

Gerade nach dem Artikel überlege ich zu verkaufen.

Was war Dein Zukauf-Grund?